TP53 status does not affect clinical parameters of response to venetoclax. (A) PB lymphocyte count. The greatest percentage reduction of PB lymphocyte count for 29 patients in M12-175 with a screening lymphocyte count ≥5 × 109/L was examined, according to the TP53 status of their CLL: neither TP53 mutated nor del(17p) (n = 12); either TP53 mutated or del(17p) (n = 7); or both TP53 mutated and del(17p) (n = 10). There was no difference in depth of reductions: ANOVA P = .71 for comparison among 3 groups. (B) Lymph nodes. The greatest percentage reduction in SPD of 6 target lymph nodes on CT on venetoclax was examined for 48 patients according to the TP53 status of their CLL: neither del(17p) nor TP53 mutated (n = 21); either TP53 mutated or del(17p) (n = 13); or both del(17p) and TP53 mutated (n = 14). There was no difference in outcome between the 3 groups (ANOVA P = .70). (C) BM CLL infiltration. The greatest percentage reduction in BM infiltration by CLL was examined for 41 patients according to the TP53 status of their CLL: neither del(17p) nor TP53 mutated (n = 19); either TP53 mutated or del(17p) (n = 10); or both TP53 mutated and del(17p) (n = 12). The 3 groups demonstrated equal reduction in BM infiltration (ANOVA P = .58).
